
Cycle 1
VEN x 28 days
AZA x 7 days
BM Biopsy
CRi/MLFS*
CR
RD/PR
Delay until ANC ≥0.5 or up to 14 days
Cycle 2
VEN x 28 days
AZA x 7 days
ANC <0.5 for ≥7 days
No severe neutropenia for ≥7 days
Delay until ANC ≥0.5 or up to 14 days
*Investigators were only recommended to consider dose reductions/pauses at any stage if subject showed evidence of CR/CRi/MLFS. Dose adjustments were not recommended in RD or PR
Cycle 3
VEN x 28 days
AZA x 7 days
Any pause due to cytopenias
No pause due to cytopenias
Delay until ANC ≥0.5, plt ≥50 x 10⁹/L or up to 14 days
Reduce all future VEN dosing to 21 days
Cycle 4
VEN x 21 days
AZA x 7 days
VEN x 28 days
BM Biopsy (every 3 cycles)
Recovery of ANC ≥0.5, plt ≥50 x 10⁹/L to > 25% above mid-cycle nadir not achieved within 14 days post cycle
Recovery of ANC ≥0.5, plt ≥50 x 10⁹/L within 14 days post cycle
No change in Azacitidine dose
BM cellularity <15%
BM cellularity 15-50%
Reduce Azacitidine dose by 33% for all future cycles
Reduce Azacitidine dose by 50% for all future cycles